This page contains brief information about tisagenlecleucel and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.
Use in Cancer
Tisagenlecleucel is approved to treat:
- B-cell acute lymphoblastic leukemia. It is used in children and adults up to 25 years old whose disease is refractory (does not respond to treatment) or has relapsed two or more times.
Tisagenlecleucel is only available as part of a special program called Kymriah REMS (Risk Evaluation and Mitigation Strategies).
Tisagenlecleucel is also being studied in the treatment of other types of cancer.
More About Tisagenlecleucel
Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.
Research Results and Related Resources
Clinical Trials Accepting Patients
Find Clinical Trials for Tisagenlecleucel - Check for trials from NCI's list of cancer clinical trials now accepting patients.